RXRX Recursion Pharmaceuticals

NEUTRAL Impact: 2/10 PRESS-RELEASE
Horizon months Filed May 29, 2026 Processed 8d 4h ago Wire GlobeNewswire
Press release: announcement
Latest settled — T+1d
RXRX ▼ -4.75% at T+1d
NEUTRAL call ✗ call lost -4.75% · α vs SPY -4.90% · entry $3.79 → $3.61
Next anchor: T+5d due yesterday
Last close $3.32 (close Jun 5) · -12.53% from $3.79 entry
Entry anchored
May 29, 04:00 PM ET
via Databento tick
T+1d
-4.75%
call -4.75% · α -4.90%
$3.61
settled 6d ago
T+5d
call — · α —
due yesterday
T+20d
call — · α —
in 22d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Recursion Pharmaceuticals granted inducement RSU awards covering ~2.99 million shares to 33 new employees under its 2024 Inducement Equity Incentive Plan, as a material inducement to their employment. The awards vest over four years with a one-year cliff. This is a routine equity grant for new hires and does not reflect any change in business operations or financial performance.

Actionable Insight

Routine inducement grants for new hires — no material impact on stock. Monitor for any future insider selling patterns or changes in employee retention, but this filing alone does not warrant trading action.

Key Facts

  • Inducement RSU awards covering 2,991,840 shares granted to 33 new employees.
  • Awards vest 1/4th on first quarterly vesting date after one-year anniversary, then 1/16th quarterly thereafter.
  • Grants made under the 2024 Inducement Equity Incentive Plan per Nasdaq Listing Rule 5635(c)(4).
  • No financial terms or performance metrics disclosed; standard new-hire equity compensation.

Financial Impact

~2.99 million shares granted, representing approximately 0.9% of outstanding shares (based on ~330M shares outstanding per market cap of $1.8B at ~$5.45/share). No cash consideration.

dilution

Risk Factors

  • Potential dilution of ~0.9% over vesting schedule, but immaterial in near term.
  • No performance conditions — awards are time-based, so retention risk if stock declines.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
57% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303818
8 reports for RXRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for RXRX — sortable, filterable
Type Now
Jun 5, 2026
1d ago
Insider Cluster
NEUTRAL ★ 2/10
$3.32 awaiting T+1awaiting T+1$3.32 (+0.00%)
May 29, 2026
8d ago
Press Release
NEUTRAL ★ 2/10
$3.79 $3.61▼ −4.75%▼ −4.90%$3.32 (−12.53%)
May 6, 2026
4w ago
Press Release
MIXED ★ 6/10
$3.43 $3.27▼ −4.66%▼ −4.33%$3.32 (−3.35%)
May 5, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.37 $3.43▲ +1.78%▲ +0.40%$3.32 (−1.63%)
Apr 7, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.19 $3.39▲ +6.27%▲ +3.73%$3.32 (+3.92%)
Mar 25, 2026
10w ago
Press Release
NEUTRAL ★ 3/10
$3.17 $3.15▼ −0.63%▲ +1.14%$3.32 (+4.57%)
Mar 17, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.42 $3.32▼ −2.92%▼ −1.53%$3.32 (−3.07%)
Feb 25, 2026
14w ago
8-K
BULLISH ★ 8/10
$3.77 $3.77· 0.00%▲ +0.55%$3.32 (−12.07%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (12h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access